Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-03-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于召开2023年第一次临时股东大会通知的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2023 first extraordinary general meeting (临时股东大会) of 康芝药业股份有限公司. It includes information about the meeting date, location, voting procedures (both onsite and online), agenda items to be voted on, registration procedures, and proxy forms. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and how to participate and vote. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement itself, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement about the meeting and voting process. The document length is 4548 characters, which is substantial but it is not a report or transcript. Therefore, the best fit is Regulatory Filings (RNS).
2023-03-03 Chinese
关于募集资金投资项目结项和终止并将剩余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 康芝药业股份有限公司 regarding the conclusion and termination of certain fundraising investment projects and the permanent supplementation of remaining raised funds into working capital. It references regulatory compliance with Shenzhen Stock Exchange rules and China Securities Regulatory Commission guidelines. The document includes detailed financial figures about raised funds, project investment progress, reasons for termination, and approvals from the board, supervisory committee, independent directors, and the sponsoring institution. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a formal regulatory announcement about the use and management of capital raised through stock issuance, specifically about changes in the use of raised funds and project status. This fits the category of Capital/Financing Update (CAP), as it updates on the company's fundraising capital usage and changes in investment projects related to raised funds. The document length (8939 characters) and content indicate it is the announcement itself, not a brief report publication notice or a certification letter. Therefore, the best classification is CAP with high confidence.
2023-03-03 Chinese
海通证券关于康芝药业募集资金投资项目结项和终止并将剩余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the verification and opinions on Kangzhi Pharmaceutical Co., Ltd.'s fundraising investment projects' completion, termination, and the permanent supplementation of remaining raised funds into working capital. It includes detailed financial figures, project progress, reasons for termination, and approvals from the board, supervisory committee, independent directors, and the sponsor institution. The document references regulatory guidelines and compliance with securities regulations. It is not a simple announcement but a comprehensive verification and opinion report on fundraising projects and fund usage. This fits the category of Capital/Financing Update (CAP), as it deals with fundraising project status, fund management, and capital allocation changes.
2023-03-03 Chinese
第六届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 康芝药业股份有限公司 regarding the conclusion and termination of certain fundraising investment projects and the permanent supplementation of remaining raised funds into working capital. It includes voting results and compliance statements with relevant laws and stock exchange rules. The document is short (787 characters) and is an official announcement of a board meeting decision rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-03-03 Chinese
关于持股5%以上股东减持股份比例达到1%暨减持计划时间过半的公告
Major Shareholding Notification Classification · 100% confidence The document is an official announcement from 康芝药业股份有限公司 regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholder's reduction plan, the amount and percentage of shares reduced, compliance with relevant securities laws and stock exchange rules, and confirms that the reduction plan is ongoing but has passed its halfway point. The document includes tables of shareholding before and after the reduction and references to regulatory filings and disclosures. There is no financial performance data, earnings information, or management discussion. The content focuses on shareholding changes by a major shareholder and compliance with disclosure requirements. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds such as 1%. The document is not a full financial report, earnings release, or management report, nor is it a proxy, dividend, or capital change announcement. Therefore, the correct classification is MRQ with high confidence.
2023-03-01 Chinese
关于公司股东减持计划预披露的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's plan to reduce their holdings in the company. It details the shareholder's identity, the number and percentage of shares to be reduced, the reasons for reduction, the method and timing, and compliance with relevant regulations. There is no financial data, no report attached or referenced as being published, and no mention of earnings, management changes, or other report types. This fits the category of a Major Shareholding Notification, which covers notifications of changes in significant share ownership levels or plans to reduce holdings.
2023-02-17 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.